The UK isn’t the only country where there have been reviews into the effectiveness and safety of puberty blockers. And it’s interesting to see what such reviews conclude when they’re not created to deliver, and staffed by people promised a peerage if they deliver, a pre-determined conclusion to support a political goal.

The latest such study comes from France. Unlike the UK Cass Review, which decided that having medical specialists involved in a review of medicine would be biased, the French study was carried out exclusively by pediatric endocrinologists.

Regarding puberty blockers, it notes that:

None of the medical treatment used in the context of hormonal transitioning have marketing authorization for this indication, but these molecules have been used for a long time in the pediatric population for other indications (precocious puberty, puberty induction…). Nevertheless, they have been used for hormonal transition in trans youth since the late 1980s in some countries, and their use in adults goes back even further. In addition, off-label prescription is very common in pediatrics and child psychiatry.

And based on the evidence, it recommends:

We recommend that puberty suppression be offered by a multidisciplinary team or network trained in supporting transgender adolescents.

In related news, a new scientific study funded by the IOC and published in the peer-reviewed British Journal of Sports Medicine demonstrates yet again that trans women do not necessarily have physical advantages over cisgender women in sports; in many cases, they have significant disadvantages in lower body strength and in lung function.

I’m sure our trans-obsessed media will cover that story, and the French study, any day now.